Lifecore Biomedical to be Added to Nasdaq Biotech Index

Rhea-AI Summary

Lifecore Biomedical (NASDAQ: LFCR) announced it will be added to the Nasdaq Biotechnology Index (NASDAQ: NBI) as part of Nasdaq's annual index reconstitution. The inclusion is expected to be effective prior to market open on Monday, December 22, 2025.

The Nasdaq Biotechnology Index tracks Nasdaq-listed securities classified as biotechnology or pharmaceutical under the Industry Classification Benchmark and is calculated using a modified capitalization-weighted methodology. Constituents are selected once annually in December and must meet eligibility requirements including minimum market capitalization, average daily trading volume, and public company seasoning.

Positive

• Inclusion in Nasdaq Biotech Index (NBI) effective Dec 22, 2025
• Meets Nasdaq eligibility criteria including market cap, ADTV, and seasoning
• Selection occurred during Nasdaq's annual December reconstitution

Negative

• None.

Key Figures

Index inclusion date December 22, 2025 Effective prior to market open for Nasdaq Biotech Index addition

Reconstitution frequency Once annually in December Nasdaq Biotechnology Index constituent selection schedule

Market Reality Check

Technical 200-day MA reported at 4064.91; pre-news price level not provided.

Market Pulse Summary

This announcement highlights Lifecore Biomedical’s expected addition to the Nasdaq Biotechnology Index, effective before the market open on December 22, 2025. Index inclusion typically reflects that a company meets specific criteria for size, trading activity, and listing history. With no recent event history provided, attention would generally turn to how this change fits into the broader business trajectory and whether future fundamentals support any visibility gained from joining a major benchmark.

Key Terms

contract development and manufacturing organization technical

"Lifecore Biomedical, Inc. ..., a fully integrated contract development and manufacturing organization"

A contract development and manufacturing organization (CDMO) is a specialized service provider that helps other companies design, test, produce and package drugs or medical products on a hired basis. Think of it as an outsourced factory and R&D partner that lets a company scale production without building its own plants. Investors watch CDMO relationships because they affect a drug’s time-to-market, manufacturing costs, supply reliability and overall project risk, all of which influence future revenue and valuation.

nasdaq biotech index financial

"stock is expected to be added to the Nasdaq Biotech Index"

A Nasdaq biotech index is a stock market benchmark that tracks the performance of biotech and pharmaceutical companies listed on the Nasdaq exchange. Think of it as a thermometer for the biotech sector: it gives investors a single number showing how the group is doing, helps compare a company or fund against the sector, and guides decisions about sector exposure, risk and diversification because biotech stocks often move together and can be more volatile than the broader market.

nasdaq biotechnology index financial

"The Nasdaq Biotechnology Index is designed to track the performance"

A stock index that tracks the performance of biotechnology companies listed on the NASDAQ stock exchange, combining many firms into a single measure of the sector’s movement. Think of it as a thermometer or basket that shows whether biotech stocks are generally rising or falling; investors use it to gauge sector health, compare individual holdings against the industry, and as the basis for funds that let you invest in the whole group at once.

industry classification benchmark technical

"classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark"

A standardized system that groups companies into industries and sectors based on their main business activities, like a library catalog that puts similar books together. It matters to investors because it enables fair comparisons between peers, guides portfolio construction and sector allocation, determines which stocks belong in industry indexes or ETFs, and helps track industry-level risks and performance trends.

capitalization-weighted methodology financial

"The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology"

A capitalization-weighted methodology is a way to build an index or portfolio where each company’s weight equals its total stock-market value, so bigger companies have bigger influence. For investors it matters because performance tracks larger firms more closely, which can make results less sensitive to small companies’ swings — like a playlist where hit songs play more often, shaping the overall listening experience.

market capitalization financial

"meet eligibility requirements, including minimum market capitalization, average daily trading volume"

Market capitalization is the total market value of a company’s outstanding shares, calculated by multiplying the current share price by the number of shares issued. It gives a quick snapshot of a company’s size and how investors value it, influencing perceived risk, index membership, and roughly how much it might cost to buy the whole company — like using a sticker price to compare the relative size and price of different houses.

average daily trading volume financial

"including minimum market capitalization, average daily trading volume, and seasoning"

The average daily trading volume is the typical number of shares or units of a security that change hands each trading day, calculated over a set period. It tells investors how active a market is—like average traffic on a road—so higher volume usually means easier, faster trades and smaller price swings when buying or selling, while low volume can make orders harder to fill and cause bigger price moves.

AI-generated analysis. Not financial advice.

CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has been notified by Nasdaq that the company’s stock is expected to be added to the Nasdaq Biotech Index (NASDAQ: NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore’s inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025.

The Nasdaq Biotechnology Index is designed to track the performance of a set of Nasdaq-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies are required to meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December.

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Lifecore Biomedical, Inc. Contact Information:

Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com

Tim Brons (Media)
415-675-7402
tbrons@vidasp.com

Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
ryan.lake@lifecore.com

FAQ

When will Lifecore Biomedical (LFCR) be added to the Nasdaq Biotech Index (NBI)?

Lifecore is expected to be added prior to market open on Monday, December 22, 2025.

What does inclusion in the Nasdaq Biotechnology Index (NBI) mean for LFCR shareholders?

Inclusion means LFCR meets Nasdaq's index eligibility criteria and will be tracked by the Nasdaq Biotechnology Index starting Dec 22, 2025.

Why was Lifecore (LFCR) selected for the Nasdaq Biotech Index during the 2025 reconstitution?

Nasdaq selects constituents annually in December; companies must meet requirements such as minimum market capitalization, average daily trading volume, and public company seasoning.

Which index methodology applies to the Nasdaq Biotechnology Index (NBI) that will include LFCR?

The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology.

How often does Nasdaq select constituents for the Nasdaq Biotechnology Index (NBI)?

Nasdaq selects constituents once annually in December during its index reconstitution process.